Litcius/Paper detail

Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial

Jean‐Michel Molina, Yazdan Yazdanpanah, Alejandro Afani Saud, Christopher Bettacchi, C. Anania, Edwin DeJesus, Stephanie O. Klopfer, Anjana Grandhi, Karen Eves, Michael Robertson, Todd Correll, Carey Hwang, George J. Hanna, Peter Sklar

2021The Lancet HIV44 citationsDOI

Topics & Concepts

LamivudineMedicineReverse-transcriptase inhibitorRegimenPlaceboInternal medicineEmtricitabineDose-ranging studyGastroenterologyHuman immunodeficiency virus (HIV)PharmacologyVirologyDouble blindViral loadAntiretroviral therapyVirusAlternative medicinePathologyHepatitis B virusHIV Research and TreatmentHIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial | Litcius